Acesso livre
Acesso livre

Terapia Intensiva

Podcast | Dicas sobre pancreatite aguda.

6 Abr, 2022 | 12:31h

#327 Acute Pancreatitis – The Curbsiders

Revisão | A perspectiva do intensivista sobre choque, gerenciamento de volume e monitoramento hemodinâmico.

6 Abr, 2022 | 12:28h

The Intensivist’s Perspective of Shock, Volume Management, and Hemodynamic Monitoring – Clinical Journal of the American Society of Nephrology

 

Comentário no Twitter

 

Efusão pericárdica e tamponamento cardíaco: dicas e armadilhas.

6 Abr, 2022 | 12:25h

Pericardial Effusion and Cardiac Tamponade: Pearls and Pitfalls – emDocs

#ACC22 – Estudo randomizado | Ácido tranexâmico reduz o risco de sangramento em pacientes submetidos a cirurgia não cardíaca.

5 Abr, 2022 | 12:26h

Tranexamic Acid in Patients Undergoing Noncardiac Surgery – New England Journal of Medicine (link para o resumo – $ para o texto completo)

Comentários:

POISE-3: Tranexamic Acid Reduces Severe Bleeding Risk in Patients Undergoing Noncardiac Surgery – American College of Cardiology

POISE-3: Tranexamic Acid Stems Bleeding During Noncardiac Surgery – TCTMD

 

Comentários no Twitter

 

Revisão sistemática | Não há evidências suficientes de que o monitoramento dos níveis séricos melhore os desfechos durante o tratamento com penicilinas.

5 Abr, 2022 | 11:51h

A systematic review of the effect of therapeutic drug monitoring on patient health outcomes during treatment with penicillins – Journal of Antimicrobial Chemotherapy

Revisão do estado de arte | A equipe neurocardíaca e o tratamento centrado no paciente de AVC isquêmico.

1 Abr, 2022 | 13:13h

The Heart Brain Team and Patient-Centered Management of Ischemic Stroke – JACC: Advances

Estudo randomizado | Tratamento precoce de pacientes ambulatoriais com plasma convalescente reduz o risco de internação para pacientes com Covid-19.

1 Abr, 2022 | 12:30h

Early Outpatient Treatment for Covid-19 with Convalescent Plasma – New England Journal of Medicine

Comentários:

Study finds convalescent plasma can be effective early COVID-19 therapy – Johns Hopkins University School of Medicine

Early Use of High-Titer Plasma Reduced COVID Hospitalizations— Randomized trial that influenced indication shows benefits in a mostly unvaccinated population – MedPage Today (necessário cadastro gratuito)

 

Comentário no Twitter

 

Uma revisão narrativa sobre a abordagem do uso de antibióticos em pacientes ventilados apresentando organismos multirresistentes em amostras respiratórias – tratar ou não tratar?

1 Abr, 2022 | 12:22h

A Narrative Review on the Approach to Antimicrobial Use in Ventilated Patients with Multidrug Resistant Organisms in Respiratory Samples—To Treat or Not to Treat? That Is the Question – Antibiotics

 

Comentário no Twitter

 

Revisão | Insuficiência cardíaca avançada: tratamento médico, diuréticos, inotrópicos e cuidados paliativos.

1 Abr, 2022 | 12:12h

Advanced heart failure: guideline-directed medical therapy, diuretics, inotropes, and palliative care – ESC Heart Failure

Estudo RECOVERY – 2 anos.

31 Mar, 2022 | 13:38h

The RECOVERY Trial – two years on – University of Oxford

Conteúdos relacionados:

How the UK found the first effective Covid-19 treatment — and saved a million lives (about the RECOVERY trial and the effects of Dexamethasone)

Covid: The London bus trip that saved maybe a million lives (about the creation of the RECOVERY Trial)

Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19 – Recovery Trial

[Preprint] RECOVERY trial shows Baricitinib reduces deaths in patients hospitalized with COVID-19.

RCT: CPAP improved outcomes in patients with acute hypoxemic respiratory failure due to COVID-19, but high-flow nasal oxygen was not better than conventional oxygen therapy.

RECOVERY Trial: No benefit from convalescent plasma in patients admitted to hospital with COVID-19.

RECOVERY Trial: Aspirin as an add-on therapy did not reduce mortality in patients hospitalized with COVID-19.

RECOVERY trial: In hospitalized COVID-19 patients with hypoxia and systemic inflammation (C-reactive protein ≥75 mg/L), tocilizumab improved survival and other clinical outcomes

RECOVERY trial: Azithromycin not beneficial for patients admitted to hospital with COVID-19

[Preprint] RECOVERY trial finds Regeneron’s monoclonal antibody combination reduces deaths for hospitalized COVID-19 patients who have not mounted their own immune response.

RECOVERY trial: Effect of hydroxychloroquine in hospitalized patients with Covid-19

Randomized trial: Lopinavir–ritonavir not beneficial for patients admitted to hospital with COVID-19

 

Comentário no Twitter

 

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.